Publication
Article
Pharmacy Times
Generic Product News
Marketed by:
APP Pharmaceuticals Inc (Schaumburg, IL)
Compared to:
Azactam (Bristol-Myers Squibb)
Indication:
APP Pharmaceuticals Inc announced the FDA approval and launch of Aztreonam for Injection USP, the first available generic equivalent to Azactam. The product is indicated for the treatment of infections caused by susceptible gram-negative microorganisms. Aztreonam for Injection USP can be used to treat a wide variety of infections, and is also intended for use as adjunctive therapy to surgery to manage infections caused by susceptible organisms.
Dosage Form:
Single-dose vials: 1 g/20 mL and 2 g/30 mL
For More Information:
847-413-2075
Anastrozole 1 mg TabletsMarketed by:
Dr. Reddy’s Laboratories (Charlotte, NC)
Compared to:
Arimidex (AstraZeneca)
Indication:Following the patent expiration of AstraZeneca’s Arimidex, a nonsteroidal aromatase inhibitor, Dr. Reddy’s announced the launch of anastrozole tablets. Dr. Reddy’s product is the bioequivalent generic version of Arimidex. It is indicated for the treatment of early breast cancer in postmenopausal women; a first-line treatment of locally advanced or metastatic breast cancer; and as a second-line treatment of advanced breast cancer that has progressed following a course of tamoxifen therapy. Nonsteroidal aromatase inhibitors slow or halt the growth of breast cancer cells by decreasing the amount of estrogen produced in the body. Anastrozole is available in 30-count bottles of 1-mg tablets.
Dosage Form: Tablets: 1 mg
For More Information:
609-627-8500
Clindamycin Palmitate Hydrochloride for Oral Solution USPMarketed by:
Paddock Laboratories Inc (Minneapolis, MN)
Compared to:
Cleocin (Pfizer)
Indication:
Paddock Laboratories recently released Clindamycin Palmitate Hydrochloride for Oral Solution USP. The medication is indicated to treat serious infections caused by susceptible anaerobic bacteria, and should be reserved for penicillin-allergic patients or other patients for whom a physician determines penicillin inappropriate. It is packaged in 100-mL bottles with a dosage strength of 75 mg/5 mL. Although symptoms may improve during the beginning of treatment, patients should complete the full course of therapy. How Supplied: Bottles: 100 mL. When reconstituted, each bottle yields a solution containing 75 mg of clindamycin per 5 mL.
For More Information:
763-546-4676 74
Omnitrope for Injection
Marketed by:
Sandoz Inc (Princeton, NJ)
Compared to:
Genotropin (Pfizer)
Indication:
Sandoz announced the FDA approval of 2 new indications for their follow-on biologic Omnitrope (somatropin [rDNA origin] for injection). The new indications include use by pediatric patients with growth failure due to Prader-Willi syndrome, and by those who are small for gestational age. Available as an easy-to-use injection pen in either 5 or 10 mg, as well as a standard 5.8-mg vial, Omnitrope offers flexible dosing and a broader injection range for patients. Omnitrope is also indicated for the treatment of pediatric patients with growth failure and for replacement therapy in adults with growth hormone deficiency.
Dosage Form:
Pen: 5 and 10 mg; Vial: 5.8 mg matched with a 1.14 mL vial of bacteriostatic water.
For More Information:
www.us.sandoz.com
609-627-8500
